MYGN Myriad Genetics, Inc. - Common Stock
About Myriad Genetics, Inc. - Common Stock Company overview from Wikipedia
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.
Read more
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.
History
The global search for the genetic basis of breast cancer began when Mary-Claire King, Ph.D., from the University of California, Berkeley announced the localization through linkage analysis of a gene associated with increased risk for breast cancer (BRCA1) to the long arm of chromosome 17.
To further locate the actual gene, Dr. Skolnick and his colleagues invented a gene mapping technique known as Restriction Fragment-length Polymorphisms (RFLP). Gilbert joined Kimberlin in 1991, and they teamed up with Skolnick to form Myriad Genetics.
In August 1994, Mark Skolnick and researchers at Myriad, along with colleagues at the University of Utah, the U.S. National Institutes of Health (NIH), and McGill University sequenced BRCA1. They attempted to patent this gene, which resulted in significant controversy and a landmark Supreme Court Case.
The firm then established the first clinical laboratory to commercialize genomic testing. Myriad created the first test to measure the molecular biology and aggressiveness of men’s prostate cancer, devised a method to assess the inherited breast cancer risk of any woman not previously diagnosed with breast cancer, regardless of ancestry, important for addressing racial and ethnic disparities, commercialized a psychotropic test that covers 61 medications commonly prescribed for depression, anxiety, ADHD. Also pioneering the field of DNA-specific medicine, Myriad received the first FDA approval for a lab-developed diagnostic test for use in predicting the responses to a DNA-repair drug.
Acquisitions and subsidiaries
In August 2016, Myriad announced it would acquire Assurex Health for up to $410 million, expanding the company's genetic testing for psychotropic medicine selection.
In July 2018, Myriad completed an acquisition of reproductive genetic testing firm Counsyl for $375 million, expanding the company's testing capabilities to carrier and prenatal screening.
Other subsidiaries of Myriad Genetics include Myriad International and Myriad Autoimmune (aka Crescendo Bioscience).
Founders
The founders of Myriad are Peter Meldrum (past President and CEO of Agridyne and past CEO and President of Myriad Genetics, Inc.) and Mark Skolnick (Adjunct Professor in the Department of Medical Informatics at the University of Utah).
Products
Among the prognostic tests developed and marketed by Myriad is "Prolaris", which uses gene expression profiling to provide a 10-year prostate cancer-specific risk of death. Another prognostic test, marketed as "myRisk Hereditary Cancer", reviews genetic markers correlated with elevated risk of developing any of eleven hereditary cancers.
Controversies
Myriad Genetics's patents on human genes became quite controversial. Following the discovery by Mary-Claire King that a gene on chromosome 17 is associated with an increased risk of breast cancer, Myriad attempted to patent this gene. These patents were the subject of scrutiny after Myriad became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc. which ruled these patents illegal. Because genes occur naturally in every human, in addition to raising moral questions, some believe that patents constitute an obstacle to biomedical research worldwide. Additionally, the discovery of their relevance to breast cancer was funded by the public.
Patent lawsuits
In 2010–2013 Myriad Genetics was a defendant in the case Association for Molecular Pathology v. Myriad Genetics (formerly Association For Molecular Pathology et al. v. United States Patent and Trademark Office).
Lawyers at the ACLU served as counsel for the plaintiffs. In the suit, medical associations, doctors, and patients sued Myriad Genetics to challenge seven United States patents on genes related to breast cancer and ovarian cancer.
Two of the company's patents on the BRCA1 and BRCA2 genes, which are inherited gene mutations that link to around half of the 5%–10% of inherited gene mutating breast cancer cases in the US[27], were ruled invalid on March 29, 2010, by Judge Robert W. Sweet in the U.S. District Court for the Southern District of New York. On appeal, the Court of Appeals for the Federal Circuit reversed the trial court in an opinion dated July 29, 2011 and held that the genes were eligible for patents. On December 7, 2011, the ACLU filed a petition for a writ of certiorari to the Supreme Court. On March 26, 2012, the Supreme Court vacated the Federal Circuit's judgment and remanded the case for further consideration in light of Mayo Collaborative Services v. Prometheus Laboratories, Inc., in which the Supreme Court had ruled, just six days earlier, that more restrictive rules were required to patent observations about natural phenomena.
On August 16, 2012, the Federal Circuit reaffirmed Myriad's right to patent the genes (because isolated genes are different from their natural state, using its own precedent in Amgen v. Chugai Pharmaceutical), although they denied patent claims on methods comprising comparison of DNA sequences, as unpatentable "mental acts". On November 30, 2012, the Supreme Court agreed to hear a second challenge to the two gene patents held by Myriad. Oral argument took place on April 15, 2013. On June 13, 2013, in Association for Molecular Pathology v. Myriad Genetics (No. 12-398), the US Supreme Court unanimously ruled that "A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated", invalidating Myriad's patents on the BRCA1 and BRCA2 genes. However, the Court also held that manipulation of a gene to create something not found in nature—such as a strand of synthetically-produced complementary DNA (cDNA)—could still be eligible for patent protection.
Myriad Genetics has also been involved in litigation in Australia over the patentability of DNA sequences (D'Arcy v Myriad Genetics Inc (2015)). Regarding BRCA1, the company succeeded in the Federal Court, both at first instance and on appeal to the full court, but in October 2015 lost in a unanimous decision of the High Court, D'Arcy v Myriad Genetics Inc.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
MYGN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
MYGN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount |
|---|---|
| July 1, 2009 | $1.7500 |
| June 15, 2009 | $1.7500 |
MYGN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 0 0.0%
- Buy 2 13.3%
- Hold 8 53.3%
- Sell 2 13.3%
- Strong Sell 3 20.0%
12-Month Price Target
7 analysts · 2026-08-17Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.25 | $-0.06 | -0.19% |
| March 31, 2026 | $-0.09 | $-0.07 | -0.02% |
| Dec. 31, 2025 | $0.04 | $-0.01 | 0.05% |
| Sept. 30, 2025 | $0.00 | $-0.01 | 0.01% |
| June 30, 2025 | $0.05 | $-0.01 | 0.06% |
| March 31, 2025 | $-0.03 | $-0.06 | 0.03% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| MYGN | $575M | -1.6 | -1.6% | -44.4% | -96.8% | 69.9% |
| AVXL | $771M | -16.5 | -36.1% | -991.4% | -47.7% | — |
| VNDA | $521M | -2.4 | 8.7% | -102.0% | -54.2% | — |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | — |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | — |
| ANIK | $133M | -12.6 | -5.9% | -9.6% | -7.5% | 56.6% |
| ELDN | $114M | -2.9 | — | — | -69.4% | — |
| ALXO | $61M | -0.6 | — | — | -225.0% | — |
| SRZN | — | — | — | — | — | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 18
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824M | $838M | $753M | $678M | $691M | $557M | $851M | $744M | $729M | $740M | $722M | |
| Cost of Revenue | $248M | $252M | $236M | $202M | · | · | · | · | $145M | $133M | $133M | |
| Gross Profit | $577M | $585M | $517M | $476M | · | · | · | · | · | · | · | |
| R&D Expense | $107M | $113M | $89M | $85M | $82M | $73M | $86M | $71M | $74M | $71M | $76M | |
| SG&A Expense | $257M | $276M | $284M | $248M | $538M | $497M | $557M | $435M | $440M | $359M | $366M | |
| Operating Expenses | $964M | $709M | $774M | $617M | $881M | $847M | $844M | $622M | $685M | $587M | $589M | |
| Operating Income | $-387M | $-124M | $-257M | $-141M | $-190M | $-290M | $8M | $122M | $44M | $153M | $134M | |
| Interest Expense | · | · | $3M | $3M | $7M | $11M | $12M | $3M | $6M | $300.0K | $200.0K | |
| Interest Income | $2M | $2M | $2M | $3M | $700.0K | $2M | $3M | $2M | $1M | $900.0K | $400.0K | |
| Other Non-op | $800.0K | $1M | $-4M | $600.0K | $139M | $15M | $1M | $-400.0K | $-3M | $2M | $500.0K | |
| Pretax Income | $-395M | $-124M | $-262M | $-141M | $-57M | $-284M | $0 | $120M | $36M | $156M | $134M | |
| Income Tax | $-29M | $4M | $1M | $-29M | $-30M | $-60M | $-4M | $-13M | $19M | $39M | $54M | |
| Net Income | $-366M | $-127M | $-263M | $-112M | $-27M | $-224M | $5M | $133M | $17M | $117M | $80M | |
| EPS (Basic) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.92 | $0.25 | $1.67 | $1.12 | |
| EPS (Diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.85 | $0.25 | $1.60 | $1.07 | |
| Shares (Basic) | 92,600,000 | 90,600,000 | 82,800,000 | 80,600,000 | 78,000,000 | 74,800,000 | 73,500,000 | 69,400,000 | 68,300,000 | 70,000,000 | 71,300,000 | |
| Shares (Diluted) | 92,600,000 | 90,600,000 | 82,800,000 | 80,600,000 | 78,000,000 | 74,800,000 | 76,000,000 | 72,000,000 | 68,800,000 | 73,400,000 | 74,500,000 | |
| EBITDA | $-387M | $-124M | $-257M | $-141M | $-190M | · | $8M | $119M | $49M | $167M | · |
Balance Sheet 29
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150M | $102M | $132M | $57M | $257M | $117M | $93M | $111M | $102M | $68M | $64M | |
| Short-term Investments | · | $0 | $9M | $58M | $81M | $34M | $44M | $70M | $48M | $90M | $81M | |
| Receivables | $115M | $121M | $114M | $102M | $91M | $90M | $134M | $100M | $89M | $92M | $86M | |
| Inventory | $31M | $28M | $22M | $20M | $15M | $27M | $31M | $34M | $42M | $38M | $25M | |
| Prepaid Expense | $25M | $30M | $19M | $20M | $21M | $14M | · | · | · | · | · | |
| Current Assets | $333M | $298M | $314M | $275M | $485M | $389M | $349M | $328M | $302M | $314M | $284M | |
| PP&E (Net) | $114M | $117M | $119M | $83M | $44M | $41M | $57M | $43M | $51M | $58M | $67M | |
| PP&E (Gross) | $202M | $227M | $239M | $193M | $150M | $154M | $169M | $157M | $148M | $142M | $138M | |
| Accum. Depreciation | $88M | $110M | $120M | $109M | $107M | $113M | $112M | $114M | $97M | $83M | $71M | |
| Goodwill | $52M | $286M | $287M | $287M | $239M | $329M | $417M | $319M | $316M | $195M | $177M | |
| Intangibles | $153M | $262M | $350M | $380M | $404M | $576M | $685M | $455M | $492M | $228M | $193M | |
| Other Non-current Assets | $6M | $8M | $15M | $16M | $8M | $2M | · | · | · | $5M | $5M | |
| Total Assets | $707M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.56B | $1.18B | $1.21B | $880M | $766M | |
| Accounts Payable | $30M | $32M | $26M | $29M | $30M | $20M | $33M | $26M | $22M | $21M | $21M | |
| Accrued Liabilities | $97M | $119M | $114M | $94M | $162M | $79M | $79M | $68M | $66M | $50M | $46M | |
| Current Liabilities | $134M | $164M | $156M | $137M | $204M | $146M | $118M | $102M | $218M | $72M | $69M | |
| Capital Leases | $83M | $88M | $97M | $131M | $79M | $51M | · | · | · | · | · | |
| Deferred Tax | · | · | · | $4M | $36M | $71M | $83M | $57M | $79M | $18M | $200.0K | |
| Other Non-current Liabilities | $2M | $2M | $41M | $18M | $6M | $15M | $8M | $6M | $7M | $8M | $4M | |
| Total Liabilities | $339M | $326M | $363M | $313M | $353M | $538M | $474M | $209M | $441M | $132M | $104M | |
| Long-term Debt | $120M | $40M | · | $0 | $0 | $225M | $234M | $9M | $99M | · | · | |
| Total Debt | $120M | $40M | $38M | · | $0 | · | $234M | $9M | · | · | · | |
| Common Stock | $900.0K | $900.0K | $900.0K | $800.0K | $800.0K | $800.0K | $700.0K | $700.0K | $700.0K | $700.0K | $700.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | $745M | |
| Retained Earnings | $-1.12B | $-757M | $-630M | $-366M | $-254M | $-227M | $26M | $54M | $-79M | $-73M | $-77M | |
| AOCI | $800.0K | $-800.0K | $-4M | $-9M | $-5M | $-2M | $-5M | $-4M | $-6M | $-10M | $-7M | |
| Stockholders' Equity | $368M | $701M | $783M | $886M | $968M | $881M | $1.09B | $966M | $768M | $740M | $662M | |
| Liabilities + Equity | $707M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.56B | $1.18B | $1.21B | $880M | $766M | |
| Shares Outstanding | 93,500,000 | 91,300,000 | 89,900,000 | 81,200,000 | 80,000,000 | 75,400,000 | 73,500,000 | 70,600,000 | 68,400,000 | 69,100,000 | 68,900,000 |
Cash Flow 13
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $54M | $61M | $62M | $53M | $63M | · | $73M | $54M | $48M | $27M | $25M | |
| Stock-based Comp | $35M | $50M | $41M | $38M | $36M | · | $34M | $27M | $30M | $32M | $46M | |
| Deferred Tax | $1M | $-2M | $-4M | $-30M | $-32M | · | $20M | $-23M | $1M | $13M | $-4M | |
| Amort. of Intangibles | $35M | $42M | $43M | $41M | $51M | · | $59M | $37M | $33M | $13M | $13M | |
| Operating Cash Flow | $2M | $-9M | $-111M | $-106M | $19M | · | $84M | $116M | $106M | $166M | $140M | |
| CapEx | · | · | · | $45M | $18M | · | $9M | $8M | $6M | $5M | $24M | |
| Investing Cash Flow | $-27M | $-12M | $32M | $-78M | $274M | · | $-286M | $-12M | $-146M | $-91M | · | |
| Stock Repurchased | · | · | · | · | $0 | · | $50M | · | $32M | $163M | $211M | |
| Net Stock Activity | · | · | · | · | $0 | · | $-50M | · | $-32M | $-163M | · | |
| Financing Cash Flow | $64M | $-7M | $153M | $-8M | $-151M | · | $182M | $-95M | $72M | $-68M | · | |
| Net Change in Cash | $39M | $-29M | $74M | $-192M | $142M | · | $-18M | $8M | $34M | $4M | $-700.0K | |
| Free Cash Flow | · | · | · | $-152M | $200.0K | · | $75M | $108M | $100M | $161M | · | |
| Levered FCF | · | · | · | $-154M | $-3M | · | · | $104M | $97M | · | · |
Profitability 8
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | · | · | · | · | · | · | · | · | · | |
| Operating Margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% | · | 0.89% | 15.4% | 6.4% | 22.1% | · | |
| Net Margin | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | · | 0.54% | 17.0% | 2.8% | 16.6% | · | |
| Pretax Margin | -47.9% | -14.7% | -34.8% | -20.7% | -8.3% | · | 0.00% | 15.1% | 5.6% | 22.4% | · | |
| EBITDA Margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% | · | 0.89% | 15.4% | 6.4% | 22.1% | · | |
| ROA | -42.2% | -11.7% | -22.4% | -8.9% | -2.0% | · | 0.34% | 11.0% | 2.1% | 15.2% | · | |
| ROE | -96.8% | -17.8% | -35.9% | -12.4% | -2.9% | · | 0.42% | 15.1% | 2.9% | 17.8% | · | |
| ROIC | -73.5% | -17.2% | -31.5% | -12.6% | -9.4% | · | · | 13.6% | 3.2% | 16.5% | · |
Liquidity & Solvency 5
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.8 | 2.0 | 2.0 | 2.4 | · | 3.0 | 3.2 | 1.5 | 4.3 | · | |
| Quick Ratio | 2.0 | 1.4 | 1.6 | 1.6 | 2.1 | · | 2.3 | 2.7 | 1.2 | 3.5 | · | |
| Debt / Equity | 0.3 | 0.1 | 0.0 | · | 0.0 | · | 0.2 | 0.0 | · | · | · | |
| LT Debt / Equity | 0.3 | 0.1 | 0.0 | · | 0.0 | · | 0.2 | 0.0 | · | · | · | |
| Interest Coverage | · | · | -88.8 | -43.9 | -28.9 | · | 0.6 | 37.1 | 8.2 | · | · |
Efficiency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.0 | 0.8 | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.6 | 0.7 | 0.9 | · | |
| Inventory Turnover | 8.5 | 10.2 | · | · | · | · | · | · | 3.6 | 4.2 | · | |
| Receivables Turnover | 7.0 | 7.1 | 7.0 | 7.0 | 7.6 | · | 7.3 | 8.2 | 7.8 | 8.5 | · |
Growth Rates 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -1.6% | 11.2% | 11.0% | -1.8% | 24.0% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 6.7% | 6.6% | 10.6% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.2% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $824M | $838M | $753M | $678M | $691M | · | $851M | $744M | $729M | $740M | $722M | |
| Net Income TTM | $-366M | $-127M | $-263M | $-112M | $-27M | · | $5M | $133M | $17M | $117M | $80M | |
| Market Cap | $575M | $1.25B | $1.72B | $1.18B | $2.21B | · | $2.04B | $2.64B | $1.77B | $2.11B | · | |
| Enterprise Value | $545M | $1.19B | $1.62B | · | $1.87B | · | $2.14B | $2.47B | · | · | · | |
| P/E | -1.6 | -9.7 | -6.0 | -10.4 | -78.9 | · | 463.0 | 20.2 | 103.4 | 19.1 | 31.8 | |
| P/S | 0.7 | 1.5 | 2.3 | 1.7 | 3.2 | · | 2.4 | 3.5 | 2.4 | 2.9 | · | |
| P/B | 1.6 | 1.8 | 2.2 | 1.3 | 2.3 | · | 1.9 | 2.7 | 2.3 | 2.8 | · | |
| P / Tangible Book | 3.5 | 8.2 | 11.8 | 5.4 | 6.8 | · | · | · | · | · | · | |
| P / Cash Flow | 319.5 | -143.9 | -15.5 | -11.1 | 121.3 | · | 24.4 | 22.8 | 16.6 | 12.7 | · | |
| P / FCF | · | · | · | -7.8 | 11040.0 | · | 27.2 | 24.5 | 17.7 | 13.1 | · | |
| EV / EBITDA | -1.4 | -9.6 | -6.3 | · | -9.8 | · | 281.4 | 20.8 | · | · | · | |
| EV / FCF | · | · | · | · | 9341.0 | · | 28.5 | 22.9 | · | · | · | |
| EV / Revenue | 0.7 | 1.4 | 2.1 | · | 2.7 | · | 2.5 | 3.3 | · | · | · | |
| Earnings Yield | -64.2% | -10.3% | -16.6% | -9.6% | -1.3% | · | 0.22% | 5.0% | 0.97% | 5.2% | 3.1% |
Income Statement 18
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $191M | $200M | $210M | $206M | $213M | $196M | $211M | $213M | $212M | $202M | $197M | $192M | $184M | $181M | $178M | $156M | |
| Cost of Revenue | $64M | $63M | $63M | $62M | $61M | $62M | $60M | $64M | $64M | $65M | $62M | $58M | $58M | $59M | $54M | $50M | |
| Gross Profit | $127M | $138M | $147M | $144M | $152M | $134M | $151M | $150M | $147M | $138M | · | · | · | · | · | · | |
| R&D Expense | $25M | $27M | $26M | $28M | $26M | $28M | $33M | $28M | $27M | $25M | $21M | $24M | $21M | $22M | $23M | $20M | |
| SG&A Expense | $58M | $62M | $56M | $68M | $67M | $66M | $63M | $69M | $72M | $71M | $-145M | $136M | $141M | $152M | $-120M | $130M | |
| Operating Expenses | $166M | $168M | $152M | $167M | $481M | $163M | $190M | $170M | $184M | $166M | $-8M | $252M | $297M | $233M | $28M | $201M | |
| Operating Income | $-39M | $-31M | $-6M | $-23M | $-329M | $-29M | $-39M | $-20M | $-36M | $-28M | $-31M | $-60M | $-114M | $-52M | $-52M | $-45M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $500.0K | · | $1M | $500.0K | $500.0K | · | $800.0K | |
| Interest Income | $400.0K | $700.0K | $800.0K | $500.0K | $200.0K | $300.0K | $300.0K | $400.0K | $400.0K | $600.0K | $700.0K | $600.0K | $500.0K | $700.0K | $1M | $1M | |
| Other Non-op | $0 | $0 | $400.0K | $400.0K | $-100.0K | $100.0K | $300.0K | $-800.0K | $-300.0K | $2M | $-700.0K | $-700.0K | $-2M | $-600.0K | $0 | $500.0K | |
| Pretax Income | $-43M | $-34M | $-9M | $-26M | $-331M | $-29M | $-39M | $-21M | $-37M | $-26M | $-32M | $-61M | $-116M | $-53M | $-52M | $-44M | |
| Income Tax | $600.0K | $0 | $-1M | $1M | $-100.0K | $-29M | $3M | $900.0K | $-500.0K | $100.0K | $-1M | $100.0K | $0 | $2M | $-10M | $-9M | |
| Net Income | $-43M | $-34M | $-8M | $-27M | $-330M | $-100.0K | $-42M | $-22M | $-37M | $-26M | $-31M | $-61M | $-116M | $-55M | $-42M | $-35M | |
| EPS (Basic) | $-0.46 | $-0.36 | $-0.09 | $-0.29 | $-3.57 | $0.00 | $-0.47 | $-0.24 | $-0.41 | $-0.29 | $-0.34 | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | |
| EPS (Diluted) | $-0.46 | $-0.36 | $-0.09 | $-0.29 | $-3.57 | $0.00 | $-0.47 | $-0.24 | $-0.41 | $-0.29 | $-0.34 | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | |
| Shares (Basic) | 94,800,000 | 93,700,000 | -184,400,000 | 93,100,000 | 92,500,000 | 91,400,000 | -180,800,000 | 90,900,000 | 90,600,000 | 89,900,000 | -162,100,000 | 81,900,000 | 81,700,000 | 81,300,000 | -160,600,000 | 80,700,000 | |
| Shares (Diluted) | 94,800,000 | 93,700,000 | -184,400,000 | 93,100,000 | 92,500,000 | 91,400,000 | -180,800,000 | 90,900,000 | 90,600,000 | 89,900,000 | -162,100,000 | 81,900,000 | 81,700,000 | 81,300,000 | -160,600,000 | 80,700,000 | |
| EBITDA | $-39M | $-31M | · | $-23M | $-329M | $-29M | · | $-20M | $-36M | $-28M | · | $-60M | $-114M | $-52M | · | $-45M |
Balance Sheet 28
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $115M | $124M | $150M | $145M | $74M | $92M | $102M | $100M | $92M | $97M | $132M | $76M | $103M | $54M | $57M | $111M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | $5M | $7M | · | $10M | $19M | $25M | · | $82M | |
| Receivables | $110M | $124M | $115M | $118M | $137M | $120M | $121M | $126M | $118M | $118M | · | $115M | $112M | $119M | · | $102M | |
| Inventory | $31M | $28M | $31M | $32M | $29M | $28M | $28M | $26M | $26M | $25M | · | $25M | $22M | $22M | · | $20M | |
| Prepaid Expense | $32M | $35M | $25M | $36M | $30M | $32M | $30M | $24M | $22M | $25M | · | $21M | $21M | $24M | · | $20M | |
| Current Assets | $289M | $313M | $333M | $345M | $284M | $287M | $298M | $293M | $292M | $290M | · | $265M | $294M | $262M | · | $352M | |
| PP&E (Net) | $109M | $112M | $114M | $111M | $113M | $114M | $117M | $115M | $116M | $118M | · | $121M | $112M | $96M | · | $68M | |
| PP&E (Gross) | $201M | $202M | $202M | $195M | $192M | $198M | $227M | $233M | $231M | $229M | · | $239M | $227M | $208M | · | $176M | |
| Accum. Depreciation | $92M | $90M | $88M | $83M | $79M | $84M | $110M | $117M | $114M | $111M | · | $118M | $115M | $112M | · | $108M | |
| Goodwill | $47M | $47M | $52M | $52M | $52M | $286M | $286M | $286M | $286M | $287M | · | $287M | $287M | $287M | · | $236M | |
| Intangibles | $139M | $146M | $153M | $163M | $170M | $258M | $262M | $312M | $320M | $341M | · | $357M | $359M | $369M | · | $371M | |
| Other Non-current Assets | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $16M | $15M | $15M | · | $16M | $22M | $18M | · | $8M | |
| Total Assets | $639M | $674M | $707M | $728M | $677M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | · | $1.15B | $1.19B | $1.17B | · | $1.21B | |
| Accounts Payable | $30M | $33M | $30M | $32M | $31M | $28M | $32M | $30M | $33M | $33M | · | $34M | $40M | $36M | · | $30M | |
| Accrued Liabilities | $93M | $90M | $97M | $108M | $101M | $112M | $119M | $111M | $98M | $99M | · | $158M | $164M | $92M | · | $85M | |
| Current Liabilities | $131M | $130M | $134M | $148M | $200M | $151M | $164M | $154M | $149M | $146M | · | $209M | $221M | $143M | · | $129M | |
| Capital Leases | $82M | $84M | $83M | $85M | $86M | $87M | $88M | $91M | $91M | $94M | · | $145M | $148M | $146M | · | $123M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $3M | $4M | $4M | · | $10M | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $34M | $35M | $41M | · | $40M | $11M | $12M | · | $5M | |
| Total Liabilities | $335M | $336M | $339M | $355M | $289M | $301M | $326M | $350M | $345M | $350M | · | $466M | $452M | $334M | · | $295M | |
| Long-term Debt | $121M | $120M | $120M | $120M | $59M | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Total Debt | $121M | $120M | · | $120M | $59M | $59M | · | $39M | $39M | $39M | · | $38M | $38M | · | · | · | |
| Common Stock | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | · | $800.0K | $800.0K | $800.0K | · | $800.0K | |
| Retained Earnings | $-1.20B | $-1.16B | $-1.12B | $-1.11B | $-1.09B | $-757M | $-757M | $-714M | $-692M | $-656M | · | $-598M | $-537M | $-421M | · | $-324M | |
| AOCI | $800.0K | $700.0K | $800.0K | $-100.0K | $-100.0K | $-600.0K | $-800.0K | $-100.0K | $-4M | $-4M | · | $-5M | $-5M | $-7M | · | $-11M | |
| Stockholders' Equity | $304M | $337M | $368M | $373M | $388M | $705M | $701M | $732M | $740M | $760M | $783M | $683M | $735M | $835M | $886M | $917M | |
| Liabilities + Equity | $639M | $674M | $707M | $728M | $677M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | · | $1.15B | $1.19B | $1.17B | · | $1.21B | |
| Shares Outstanding | 95,600,000 | 94,400,000 | 93,500,000 | 93,100,000 | 93,100,000 | 92,200,000 | 91,300,000 | 91,000,000 | 90,900,000 | 90,500,000 | 89,900,000 | 82,100,000 | 81,900,000 | 81,500,000 | 81,200,000 | 80,900,000 |
Cash Flow 11
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $12M | $13M | $13M | $14M | $14M | $15M | $16M | $15M | $16M | $15M | $14M | $13M | $19M | $14M | $13M | |
| Stock-based Comp | $7M | $6M | $3M | $12M | $11M | $10M | $11M | $12M | $14M | $12M | $10M | $12M | $11M | $8M | $8M | $9M | |
| Amort. of Intangibles | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $10M | $11M | $11M | $11M | $11M | $11M | $11M | $10M | $10M | |
| Operating Cash Flow | $-8M | $-16M | $11M | $21M | $-14M | $-16M | $7M | $700.0K | $3M | $-19M | $-55M | $-22M | $-900.0K | $-33M | $-7M | $-2M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | $19M | $24M | · | $18M | |
| Investing Cash Flow | $-3M | $-6M | $-6M | $-6M | $-7M | $-8M | $-6M | $8M | $-6M | $-7M | $-12M | $-2M | $12M | $35M | $-36M | $11M | |
| Financing Cash Flow | $2M | $-3M | $-8M | $56M | $3M | $14M | $2M | $-3M | $2M | $-9M | $122M | $-2M | $38M | $-5M | $-2M | $-4M | |
| Net Change in Cash | $-9M | $-25M | $-4M | $71M | $-17M | $-11M | $2M | $9M | $-4M | $-35M | $56M | $-28M | $50M | $-3M | $-44M | $5M | |
| Taxes Paid | $400.0K | $-12M | · | · | $0 | $300.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-57M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-57M | · | · |
Profitability 8
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.6% | 68.7% | · | 69.9% | 71.2% | 68.5% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | -20.4% | -15.3% | · | -11.3% | -154.5% | -14.8% | · | -9.4% | -17.3% | -13.8% | · | -31.3% | -62.0% | -28.8% | · | -28.8% | |
| Net Margin | -22.7% | -17.0% | · | -13.3% | -155.1% | -0.05% | · | -10.4% | -17.3% | -12.9% | · | -31.9% | -63.3% | -30.2% | · | -22.4% | |
| Pretax Margin | -22.3% | -17.0% | · | -12.7% | -155.1% | -15.0% | · | -9.9% | -17.6% | -12.8% | · | -31.9% | -63.3% | -29.0% | · | -28.3% | |
| EBITDA Margin | -20.4% | -15.3% | · | -11.3% | -154.5% | -14.8% | · | -9.4% | -17.3% | -13.8% | · | -31.3% | -62.0% | -28.8% | · | -28.8% | |
| ROA | -6.6% | -4.1% | · | -3.0% | -37.5% | -0.01% | · | -2.0% | -3.2% | -2.3% | · | -5.2% | -9.7% | -4.5% | · | -2.8% | |
| ROE | -12.5% | -6.5% | · | -5.0% | -58.6% | -0.01% | · | -3.1% | -5.0% | -3.3% | · | -7.7% | -13.8% | -6.1% | · | -3.7% | |
| ROIC | -9.3% | -6.7% | · | -5.0% | -73.5% | -0.01% | · | -2.7% | -4.6% | -3.5% | · | -8.3% | -14.7% | -6.5% | · | -3.9% |
Liquidity & Solvency 5
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.4 | · | 2.3 | 1.4 | 1.9 | · | 1.9 | 2.0 | 2.0 | · | 1.3 | 1.3 | 1.8 | · | 2.7 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.8 | 1.1 | 1.4 | · | 1.5 | 1.4 | 1.5 | · | 1.0 | 1.1 | 1.4 | · | 2.3 | |
| Debt / Equity | 0.4 | 0.4 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | 0.3 | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -55.8 | · | -60.1 | -227.4 | -104.4 | · | -56.2 |
Efficiency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 2.1 | 2.2 | · | 2.1 | 2.2 | 2.3 | · | 2.5 | 2.7 | 2.8 | · | 2.6 | 3.1 | 3.2 | · | · | |
| Receivables Turnover | 1.5 | 1.6 | · | 1.7 | 1.7 | 1.6 | · | 1.8 | 1.8 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 1.6 |
Valuation (TTM) 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $810M | $815M | · | $828M | $834M | $823M | · | $819M | $789M | $759M | · | $713M | $700M | $682M | · | $668M | |
| Net Income TTM | $-435M | $-392M | · | $-380M | $-389M | $-85M | · | $-146M | $-240M | $-258M | · | $-267M | $-220M | $-124M | · | $-45M | |
| Market Cap | $546M | $425M | · | $673M | $494M | $818M | · | $2.49B | $2.22B | $1.93B | · | $1.32B | $1.90B | $1.89B | · | $1.54B | |
| Enterprise Value | $551M | $421M | · | $647M | $479M | $785M | · | $2.43B | $2.16B | $1.86B | · | $1.27B | $1.82B | · | · | · | |
| P/E | -1.2 | -1.1 | · | -1.8 | -1.3 | -9.4 | · | -16.2 | -8.5 | -6.8 | · | -4.9 | -8.6 | -15.1 | · | -33.5 | |
| P/S | 0.7 | 0.5 | · | 0.8 | 0.6 | 1.0 | · | 3.0 | 2.8 | 2.5 | · | 1.8 | 2.7 | 2.8 | · | 2.3 | |
| P/B | 1.8 | 1.3 | · | 1.8 | 1.3 | 1.2 | · | 3.4 | 3.0 | 2.5 | · | 1.9 | 2.6 | 2.3 | · | 1.7 | |
| P / Tangible Book | 4.6 | 2.9 | · | 4.3 | 3.0 | 5.1 | · | 18.8 | 16.5 | 14.6 | · | 32.8 | 21.3 | 10.6 | · | 5.0 | |
| P / Cash Flow | · | -27.1 | · | · | · | -50.2 | · | · | · | -103.7 | · | · | · | -57.0 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | -33.4 | · | · | |
| EV / EBITDA | -14.2 | -13.7 | · | -27.8 | -1.5 | -27.1 | · | -121.6 | -59.3 | -66.8 | · | -21.1 | -16.0 | · | · | · | |
| EV / Revenue | 0.7 | 0.5 | · | 0.8 | 0.6 | 1.0 | · | 3.0 | 2.7 | 2.5 | · | 1.8 | 2.6 | · | · | · | |
| Earnings Yield | -82.0% | -93.8% | · | -56.7% | -79.5% | -10.6% | · | -6.2% | -11.7% | -14.7% | · | -20.4% | -11.7% | -6.6% | · | -3.0% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $824M | $838M | $753M | $678M | $691M |
| Gross Margin % | 69.9% | 69.9% | — | — | — |
| Operating Margin % | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% |
| Net Income | $-366M | $-127M | $-263M | $-112M | $-27M |
| Diluted EPS | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debt / Equity | 0.3 | 0.1 | 0.0 | — | 0.0 |
| Current Ratio | 2.5 | 1.8 | 2.0 | 2.0 | 2.4 |
| Quick Ratio | 2.0 | 1.4 | 1.6 | 1.6 | 2.1 |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | — | — | — | $-152M | $200.0K |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 220 filers · $346.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 52 (+16 vs prior Q) | 43 (-2 vs prior Q) | 65 (-6 vs prior Q) | 56 (-6 vs prior Q) | -124.3M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | $37,802,324 | 6,620,372 | 10.92% | Shares |
| Vestal Point Capital, LP | $32,746,850 | 5,735,000 | 9.46% | Shares |
| STATE STREET CORP | $28,464,693 | 4,985,060 | 8.22% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $23,304,657 | 4,081,376 | 6.73% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $17,584,916 | 3,079,670 | 5.08% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $11,816,625 | 2,068,833 | 3.41% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $10,800,619 | 1,891,527 | 3.12% | Shares |
| Camber Capital Management LP | $10,620,000 | 2,000,000 | 3.07% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9,939,934 | 1,740,794 | 2.87% | Shares |
| Qube Research & Technologies Ltd | $9,511,918 | 1,665,835 | 2.75% | Shares |
| TWO SIGMA INVESTMENTS, LP | $8,894,621 | 1,557,727 | 2.57% | Shares |
| MACKENZIE FINANCIAL CORP | $8,768,858 | 1,535,702 | 2.53% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $8,012,306 | 1,403,206 | 2.31% | Shares |
| Aberdeen Group plc | $7,474,007 | 1,308,933 | 2.16% | Shares |
| CITADEL ADVISORS LLC | $6,482,323 | 1,135,258 | 1.87% | Shares |
| D. E. Shaw & Co., Inc. | $6,107,827 | 1,069,672 | 1.76% | Shares |
| GOLDMAN SACHS GROUP INC | $5,962,085 | 1,044,148 | 1.72% | Shares |
| Assenagon Asset Management S.A. | $5,889,659 | 1,031,464 | 1.70% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $5,272,317 | 923,348 | 1.52% | Shares |
| Man Group plc | $5,188,865 | 908,733 | 1.50% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $4,469,588 | 782,765 | 1.29% | Shares |
| FMR LLC | $4,398,921 | 770,389 | 1.27% | Shares |
| BANK OF AMERICA CORP /DE/ | $4,232,618 | 741,264 | 1.22% | Shares |
| Cubist Systematic Strategies, LLC | $3,840,296 | 531,161 | 1.11% | Shares |
| VANGUARD GROUP INC | $3,620,327 | 588,671 | 1.05% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $3,555,172 | 622,622 | 1.03% | Shares |
| AMH Equity Ltd | $2,892,000 | 400,000 | 0.84% | Shares |
| PRUDENTIAL FINANCIAL INC | $2,819,958 | 493,863 | 0.81% | Shares |
| Walleye Capital LLC | $2,653,134 | 464,647 | 0.77% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $2,567,998 | 449,737 | 0.74% | Shares |
| OP Asset Management Ltd | $2,567,313 | 449,617 | 0.74% | Shares |
| BlackRock, Inc. | $2,498,850 | 437,627 | 0.72% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,341,831 | 410,128 | 0.68% | Shares |
| Squarepoint Ops LLC | $2,190,921 | 383,699 | 0.63% | Shares |
| TWO SIGMA ADVISERS, LP | $2,092,230 | 340,200 | 0.60% | Shares |
| Militia Capital Management LLC | $1,720,994 | 301,400 | 0.50% | Shares |
| AMERIPRISE FINANCIAL INC | $1,488,677 | 260,714 | 0.43% | Shares |
| Point72 Asset Management, L.P. | $1,363,411 | 238,776 | 0.39% | Shares |
| XTX Topco Ltd | $1,353,407 | 237,024 | 0.39% | Shares |
| Jain Global LLC | $1,305,072 | 228,559 | 0.38% | Shares |
| ExodusPoint Capital Management, LP | $1,211,542 | 212,179 | 0.35% | Shares |
| Voleon Capital Management LP | $1,209,132 | 211,757 | 0.35% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $1,169,671 | 204,846 | 0.34% | Shares |
| MOORE CAPITAL MANAGEMENT, LP | $1,076,483 | 188,526 | 0.31% | Shares |
| Vanguard Global Advisers, LLC | $1,027,332 | 179,918 | 0.30% | Shares |
| MARTINGALE ASSET MANAGEMENT L P | $1,019,498 | 178,546 | 0.29% | Shares |
| Bank of New York Mellon Corp | $939,917 | 164,609 | 0.27% | Shares |
| FEDERATED HERMES, INC. | $932,831 | 163,368 | 0.27% | Shares |
| VOYA INVESTMENT MANAGEMENT LLC | $842,648 | 147,574 | 0.24% | Shares |
| CANADA PENSION PLAN INVESTMENT BOARD | $790,264 | 138,400 | 0.23% | Shares |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $781,453 | 136,857 | 0.23% | Shares |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $756,969 | 132,569 | 0.22% | Shares |
| Engineers Gate Manager LP | $712,431 | 124,769 | 0.21% | Shares |
| RHUMBLINE ADVISERS | $687,490 | 120,403 | 0.20% | Shares |
| CITIGROUP INC | $636,562 | 111,482 | 0.18% | Shares |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $630,190 | 110,366 | 0.18% | Shares |
| State of Wyoming | $615,441 | 107,783 | 0.18% | Shares |
| Mariner, LLC | $555,463 | 97,276 | 0.16% | Shares |
| Inspire Investing, LLC | $520,766 | 115,726 | 0.15% | Shares |
| DEUTSCHE BANK AG\ | $515,253 | 90,237 | 0.15% | Shares |
| AMERICAN CENTURY COMPANIES INC | $490,301 | 85,867 | 0.14% | Shares |
| Rafferty Asset Management, LLC | $478,618 | 83,821 | 0.14% | Shares |
| ZACKS INVESTMENT MANAGEMENT | $464,749 | 81,392 | 0.13% | Shares |
| ALLIANCEBERNSTEIN L.P. | $436,838 | 97,075 | 0.13% | Shares |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $420,425 | 72,114 | 0.12% | Shares |
| MERCER GLOBAL ADVISORS INC /ADV | $416,579 | 72,956 | 0.12% | Shares |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $401,567 | 89,237 | 0.12% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $396,932 | 69,515 | 0.11% | Shares |
| OSAIC HOLDINGS, INC. | $373,171 | 65,354 | 0.11% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $361,906 | 63,381 | 0.10% | Shares |
| Quantinno Capital Management LP | $340,122 | 59,566 | 0.10% | Shares |
| UMB Bank, n.a. | $325,470 | 57,000 | 0.09% | Shares |
| CWM, LLC | $320,189 | 71,153 | 0.09% | Shares |
| MetLife Investment Management, LLC | $315,974 | 55,337 | 0.09% | Shares |
| NewEdge Advisors, LLC | $299,118 | 52,385 | 0.09% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $286,000 | 50,000 | 0.08% | Shares |
| BARCLAYS PLC | $273,749 | 47,942 | 0.08% | Shares |
| Russell Investments Group, Ltd. | $272,623 | 47,745 | 0.08% | Shares |
| TUDOR INVESTMENT CORP ET AL | $255,123 | 44,680 | 0.07% | Shares |
| Quadrature Capital Ltd | $252,182 | 44,165 | 0.07% | Shares |
| PROFUND ADVISORS LLC | $243,743 | 42,687 | 0.07% | Shares |
| EntryPoint Capital, LLC | $227,469 | 39,837 | 0.07% | Shares |
| Verdad Advisers, LP | $214,125 | 37,500 | 0.06% | Shares |
| AXQ CAPITAL, LP | $211,967 | 37,122 | 0.06% | Shares |
| Balyasny Asset Management L.P. | $210,471 | 36,860 | 0.06% | Shares |
| AIMZ Investment Advisors, LLC | $205,903 | 36,060 | 0.06% | Shares |
| Invesco Ltd. | $205,748 | 36,033 | 0.06% | Shares |
| CITADEL ADVISORS LLC | $184,433 | 32,300 | 0.05% | Call option |
| JANUS HENDERSON GROUP PLC | $177,611 | 39,469 | 0.05% | Shares |
| UBS Group AG | $172,573 | 30,223 | 0.05% | Shares |
| Graham Capital Management, L.P. | $164,471 | 28,804 | 0.05% | Shares |
| Nuveen, LLC | $158,892 | 27,827 | 0.05% | Shares |
| NEW YORK STATE COMMON RETIREMENT FUND | $157,253 | 27,540 | 0.05% | Shares |
| WOLVERINE TRADING, LLC | $144,700 | 20,000 | 0.04% | Call option |
| Arax Advisory Partners | $144,292 | 25,270 | 0.04% | Shares |
| CAPTRUST FINANCIAL ADVISORS | $144,240 | 25,261 | 0.04% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $143,646 | 25,157 | 0.04% | Shares |
| Police & Firemen's Retirement System of New Jersey | $143,601 | 25,149 | 0.04% | Shares |
| IEQ CAPITAL, LLC | $137,040 | 24,000 | 0.04% | Shares |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $131,655 | 23,057 | 0.04% | Shares |
Company insiders 40 insiders · 15 officers · 16 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Samraat S. Raha | President and CEO | June 11, 2026 A | 1,068,083 | 0 | 0 | $0 |
| Paul J Diaz | President and CEO | March 24, 2022 F | 1,159,429 | 0 | 0 | $0 |
| Jay M Moyes | Chief Financial Officer | Oct. 15, 2007 M | 25,282 | 0 | 0 | $0 |
| Peter D Meldrum | President & C.E.O. | May 6, 2015 M | 10,424 | 0 | 0 | $0 |
| Craig T Benson | President, Myriad RBM | Sept. 17, 2013 A | — | 0 | 0 | $0 |
| Gregory C Critchfield | President Myriad Genetic Labs | Sept. 15, 2009 A | 129,546 | 0 | 0 | $0 |
| Brian J Donnelly | Chief Commerical Officer | June 11, 2026 A | 573,363 | 0 | 0 | $0 |
| Raj Jampa | Chief Technology Officer | June 1, 2026 A | 251,889 | 0 | 0 | $0 |
| Jerry S Lanchbury | Chief Scientific Officer | Oct. 9, 2021 F | 264,324 | 0 | 0 | $0 |
| Gary A. King | Exec. VP International Ops | Sept. 30, 2019 D | 148,397 | 0 | 0 | $0 |
| Richard M Marsh | E.V.P., General Counsel | Sept. 30, 2018 D | 144,174 | 0 | 0 | $0 |
| Mark H Skolnick | Chief Scientific Officer | Nov. 5, 2009 M | 34,000 | 0 | 0 | $0 |
| Adrian N Hobden | Pres. Myriad Pharmaceuticals | June 8, 2009 M | 234,071 | 0 | 0 | $0 |
| William A Hockett III | V. P. of Corp Communications | Sept. 10, 2008 A | 9,001 | 0 | 0 | $0 |
| George S Simon | V.P. Business Development | Jan. 12, 2007 M | 2,278 | 0 | 0 | $0 |
| Rashmi Kumar | Director | June 8, 2026 S | 171,889 | 0 | 1 | $-66,843 |
| Mark Steven Davis | Director | June 4, 2026 A | 106,665 | 0 | 0 | $0 |
| Lee Nisley Newcomer | Director | June 4, 2026 A | 191,842 | 0 | 0 | $0 |
| Daniel Skovronsky | Director | June 4, 2026 A | 195,507 | 0 | 0 | $0 |
| Colleen F Reitan | Director | June 4, 2026 A | 152,030 | 0 | 0 | $0 |
| Louise S. Phanstiel | Director | June 4, 2026 A | 341,652 | 0 | 0 | $0 |
| Heinrich Dreismann | Director | June 4, 2026 A | 231,145 | 0 | 0 | $0 |
| Paul Bisaro | Director | June 4, 2026 A | 157,142 | 1 | 0 | $27,600 |
| Lawrence C Best | Director | Dec. 5, 2019 A | 60,790 | 0 | 0 | $0 |
| Linda S Wilson | Director | Jan. 7, 2010 M | 2,500 | 0 | 0 | $0 |
| Dale A Stringfellow | Director | Feb. 17, 2005 A | — | 0 | 0 | $0 |
| Arthur H Hayes JR | Director | Nov. 12, 2003 A | — | 0 | 0 | $0 |
| MYRIAD GENETICS INC | 10% owner | June 17, 2009 J | 0 | 0 | 0 | $0 |
| Benjamin Richard Wheeler | — | Aug. 16, 2026 F | 289,748 | 0 | 0 | $0 |
| Daniel K Spiegelman | — | June 4, 2024 S | 32,917 | 0 | 0 | $0 |
| Dennis Langer | — | Aug. 3, 2021 M | 89,527 | 0 | 0 | $0 |
| Heinrich Dreismann | — | June 3, 2021 A | 83,527 | 0 | 0 | $0 |
| Walter Gilbert PHD | — | Dec. 13, 2019 P | 54,150 | 0 | 0 | $0 |
| John T Henderson | — | Dec. 5, 2019 A | 76,040 | 0 | 0 | $0 |
| Mark Christopher Capone | — | Sept. 30, 2019 D | 522,216 | 0 | 0 | $0 |
| Walter Lloyd Sanders | — | Sept. 30, 2018 D | 36,195 | 0 | 0 | $0 |
| James S Evans | — | Sept. 30, 2014 M | 48,128 | 0 | 0 | $0 |
| Wayne W Laslie | — | May 8, 2009 M | 44,260 | 0 | 0 | $0 |
| Robert S Attiyeh | — | Nov. 13, 2008 A | 3,000 | 0 | 0 | $0 |
| Arthur Hull Hayes JR | — | Nov. 15, 2007 A | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 41 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| GNOM · Global X Funds | 0.35% | 48,961 NS | May 31, 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.30% | 211,853 NS | May 31, 2026 | N-PORT |
| HAPS · Harbor ETF Trust | 0.27% | 88,226 NS | April 30, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.12% | 125,944 NS | April 30, 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.05% | 130,295 NS | May 31, 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0.04% | 100,214 NS | April 30, 2026 | N-PORT |
| FNDA · SCHWAB STRATEGIC TRUST | 0.02% | 492,881 NS | May 31, 2026 | N-PORT |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0.01% | 17,035 NS | April 30, 2026 | N-PORT |
| RSSL · Global X Funds | 0.01% | 40,139 NS | April 30, 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.01% | 68,802 NS | May 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.01% | 275,229 NS | April 30, 2026 | N-PORT |
| ITWO · ProShares Trust | 0.01% | 4,334 NS | May 31, 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 443,693 NS | May 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 41,272 NS | April 30, 2026 | N-PORT |
| UWM · ProShares Trust | 0.01% | 3,389 NS | May 31, 2026 | N-PORT |
| URTY · ProShares Trust | 0.00% | 3,427 NS | May 31, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 8,932 NS | April 30, 2026 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0.00% | 6,352 NS | May 31, 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 3,176 NS | May 31, 2026 | N-PORT |
| HDG · ProShares Trust | 0.00% | 86 NS | May 31, 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 54,235 NS | May 31, 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.00% | 2,500 NS | May 31, 2026 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.00% | 3 NS | May 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VFQY · VANGUARD WELLINGTON FUND | — | — | July 30, 2026 | Daily |
| VFVA · VANGUARD WELLINGTON FUND | — | — | July 30, 2026 | Daily |
| VFMF · VANGUARD WELLINGTON FUND | — | — | July 30, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| ITOT · iShares Trust | — | — | Aug. 4, 2026 | Daily |
| IWV · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IWN · iShares Trust | — | — | Aug. 17, 2026 | Daily |
| IWM · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IBB · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | July 13, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | — | — | July 13, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | — | — | July 20, 2026 | Daily |
| SMLF · iShares Trust | — | — | Aug. 10, 2026 | Daily |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | July 20, 2026 | Daily |